Showing 1 - 7 results of 7 for search 'Yoshitake Murayama', query time: 1.19s Refine Results
  1. 1
    Clinical significance of primary prophylactic pegylated‐granulocyte‐colony stimulating factor after the administration of ramucirumab plus docetaxel in patients with previously treated non‐small cell lung cancer
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Potential of FDG-PET as Prognostic Significance after anti-PD-1 Antibody against Patients with Previously Treated Non-Small Cell Lung Cancer
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Improved efficacy of ramucirumab plus docetaxel after nivolumab failure in previously treated non‐small cell lung cancer patients
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Different incidence of interstitial lung disease according to different kinds of EGFR‐tyrosine kinase inhibitors administered immediately before and/or after anti‐PD‐1 antibodies in lung cancer
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Radiotherapy is an independent prognostic marker of favorable prognosis in non‐small cell lung cancer patients after treatment with the immune checkpoint inhibitor, nivolumab
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    Severe hepatotoxicity due to osimertinib after nivolumab therapy in patients with non‐small cell lung cancer harboring EGFR mutation
    Get full text
    Article
    Save to List
    Saved in:
  7. 7
    Chemoradiotherapy followed by durvalumab in patients with unresectable advanced non‐small cell lung cancer: Management of adverse events
    Get full text
    Article
    Save to List
    Saved in:
Search Tools: RSS Feed – Email Search